15d-PGJ2 inhibits cell growth and induces apoptosis of MCG-803 human gastric cancer cell line

World Journal of Gastroenterology

Volumn 9, Issue 10, 2003, Pages 2149-2153

  Chen, Yun Xian ^a   Zhong, Xue Yun ^b   Qin, Yan Fang ^b   Bing, Wang ^b   He, Li Zhen ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; BETA ACTIN; CYCLOOXYGENASE 2; LIGAND; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; THYMIDINE; TRITIUM; 15 DEOXYPROSTAGLANDIN J2; 15-DEOXYPROSTAGLANDIN J2; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; CELL RECEPTOR; CYCLOOXYGENASE 1; DRUG DERIVATIVE; ISOENZYME; MEMBRANE PROTEIN; ONCOPROTEIN; PROSTAGLANDIN D2; PROTEIN BCL X; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; NICK END LABELING; NORTHERN BLOTTING; PROSTAGLANDIN SYNTHESIS; RADIOIMMUNOASSAY; STAINING; STOMACH CANCER; SUPERNATANT; WESTERN BLOTTING; CELL DIVISION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; STOMACH TUMOR; TUMOR CELL LINE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CELL DIVISION; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN D2; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 0142152189     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i10.2149     Document Type: Article

References (56)

1. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci 1997; 94: 4312-4317
2. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci 1997; 94: 4318-4323
3. Saffaf P, Mueller E, Jones D, King F, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nature Med 1998; 4: 1046-1052
4. Brockman JA, Gupta RA, Dubois RN. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998; 115: 1049-1055
5. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997; 272: 18779-18789
6. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J. Activation of the peroxisome proliferator-activated receptor g promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nature Med 1998; 4: 1053-1057
7. Saez E, Tontonoz P, Nelson MC, Alvarez JGA, Ming T, Baird SM, Thomazy VA, Evans RM. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4: 1058-1061
8. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Burn RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 1997; 94: 237-241
9. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-3352
10. Elstner E, Muller C, Koshizuka K, Willamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998; 95: 8806-8811
11. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-895
12. Spiegelman BM. PPARgamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514
13. Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W. Positive regulation of the peroxisome beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol Cell 1993; 77: 67-76
14. Kliewer SA, Umesono K, Noonan D, Heyman R, Evans RM. Positive regulation of the peroxisome beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Nature 1992; 358: 771-774
15. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996; 12: 335-363
16. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 1992; 11: 433-439
17. Vanden Heuvel JP. Peroxisome proliferator-activated receptors (PPARs) and carcinogenesis. Toxicol Sci 1999; 47: 1-8
18. Yu K, Bayona W, Kaline CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995; 270: 23975-23983
19. Straus DS, Glass CK. Cyclopentenone prostaglandins: New insights on biological activities and cellular targets. Med Res Rev 2001; 21: 185-210
20. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor g is a negative regulator of macrophage activation. Nature 1998; 391: 79-82
21. Jiang C, Ting A, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86
22. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor-γ inhibit growth, and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86: 2170-2177
23. Reed JC. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behring Inst Mitt 1996; 97: 72-100
24. Susin SA, Lorenzo HK, Zamzami N. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397: 441-446
25. Lavoie JN, Nguyen M, Marcellus RC, Brantou PE, Shore GC. E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVAD-fmk. J Cell Biol 1998; 140: 637-645
26. Schlapbach R, Fontana A. Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycin-induced apoptosis of glioma cells. Biochim. Biophys. Acta 1997; 1359: 174-180
27. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 1997; 139: 1281-1292
28. Rosse T, Olivier R, Monney L, Rager M, Conus S, Fellay I, Jansen B, Borner C. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 1998; 391: 496-499
29. Vaux DL. CED-4 - The third horseman of apoptosis. Cell 1997; 90: 389-390
30. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405-413
31. Pan G, Humke EW, Dixit VM. Activation of caspases triggered by cytochrome c in vitro. FEBS Lett 1998; 426: 151-154
32. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073
33. Herschman HR. Prostaglandin synthase 2. Biochem Bioph Acta 1996; 1299: 125-140
34. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998; 90: 1609-1620
35. Eberhart CE, Coffery RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188
36. Hao X, Bishop AE, Wallace M, Wang H, Willcocks TC, Maclouf J, Polak JM, Knight S, Talbot IC. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999; 187: 295-301
37. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929-2934
38. Ristimaki A, Honkanen N, Jankala H. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-1280
39. Wolff H, Ssukkonen K, Anttila S, Karjalainen A, Vainio H, Restimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58: 4997-5001
40. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59: 5647-5650
41. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501
42. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996; 56: 733-737
43. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998; 95: 681-686
44. Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55: 3310-3116
45. Hanif R, Pittas A, Feng Y, Koutsos ML, Qiao L, Staiano-Coico L. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237-245
46. Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 1997; 57: 267-271
47. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-1423
48. Williams CS, Tsujii M, Reese J, Dey SK, Dubois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589-1594
49. Zhang X, Morham SG, Langenbach R, Young DA. Malignant transformation and antineoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999; 190: 451-459
50. Hla T, Ristimaki A, Appleby S, Barriocanal JG. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann N Y Acad Sci 1993; 696: 197-204
51. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part 1). J Natl Cancer Inst 1998; 90: 1529-1536
52. Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC. Cyclooxygenase-1 and -2 isoenzymes. Inst J Biochem Cell Biol 1999; 31: 551-557
53. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000; 1470: M69-78
54. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58: 4245-4249
55. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58: 362-366
56. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by block Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275: 11397-11403